文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

川崎病患者静脉注射免疫球蛋白抵抗的预测因素。

Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.

机构信息

Department of Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510120, China.

Department of Pediatric Cardiovascular, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.

出版信息

Int J Clin Pract. 2022 Aug 3;2022:2726686. doi: 10.1155/2022/2726686. eCollection 2022.


DOI:10.1155/2022/2726686
PMID:35989868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9365590/
Abstract

BACKGROUND: Between 10 and 20% of Kawasaki disease (KD) patients are resistant to treatment with initial intravenous immunoglobulin (IVIG) and have a high risk of developing coronary artery lesions. Some studies have been conducted to identify predictive factors. However, the results are controversial. This study aims to identify the risk factors for IVIG-resistant KD patients in a Chinese population. METHODS: We performed a retrospective analysis of medical records of consecutive KD patients from two medical centers in South China from January 2015 to December 2017. A total of 1281 KD patients were eligible for inclusion in this study and maintained follow-up for over 12 months. The KD patients were divided into two groups based on IVIG response. Clinical characteristics and laboratory variables were compared between the two groups. Multivariate logistic regression analysis was performed to identify the risk factors of IVIG resistance in KD patients. RESULTS: Of the 1281 KD patients, 141 (11.0%) cases who were IVIG resistant to adjunctive therapies for primary treatment were classified as group 1. The remaining patients were in group 2 ( = 1140), classified as the control group. There was a significant difference in male to female ratio and the length of hospital stay between the two groups ( < 0.05). Group 1 had a higher white blood cell count (=0.01) and C-reactive protein level ( < 0.01) before IVIG treatment than in group 2. Group 1 had a significantly higher white blood cell count and percentage of neutrophils after the IVIG infusion than in group 2 ( < 0.001). In addition, the mean values of C-reactive protein level and neutrophil percentage before and after treatment difference comparison were significantly different. Multivariate analysis showed that patients presenting with coronary artery lesions in the acute phase and a C-reactive protein level >100 mg/L at diagnosis were associated with IVIG resistance in KD. During the 12-month follow-up period, group 1 had an obviously higher incidence of coronary artery lesions than group 2, and the difference between the groups was statistically significant ( < 0.001). CONCLUSIONS: Patients presenting with coronary artery lesions in the acute phase and elevated C-reactive protein levels before IVIG treatment might be a useful and important value for predicting IVIG resistance in KD. Risk assessment based on coronary artery lesions and C-reactive protein levels prior to the treatment may improve the outcome of IVIG resistance.

摘要

背景:10%至 20%的川崎病(KD)患者对初始静脉注射免疫球蛋白(IVIG)治疗有耐药性,并且发生冠状动脉损伤的风险较高。已经进行了一些研究来确定预测因素。但是,结果存在争议。本研究旨在确定中国人群中 IVIG 耐药性 KD 患者的危险因素。

方法:我们对 2015 年 1 月至 2017 年 12 月期间来自中国南方两个医学中心的连续 KD 患者的病历进行了回顾性分析。共有 1281 例 KD 患者符合纳入本研究标准,并进行了超过 12 个月的随访。根据 IVIG 反应将 KD 患者分为两组。比较两组之间的临床特征和实验室变量。进行多变量 logistic 回归分析以确定 KD 患者 IVIG 耐药的危险因素。

结果:在 1281 例 KD 患者中,141 例(11.0%)患者在初始治疗中添加辅助治疗后对 IVIG 耐药,分为组 1。其余患者为组 2(n=1140),为对照组。两组之间的男女比例和住院时间存在显著差异(<0.05)。与组 2 相比,组 1 在 IVIG 治疗前的白细胞计数(=0.01)和 C 反应蛋白水平(<0.01)较高。与组 2 相比,组 1 在 IVIG 输注后白细胞计数和中性粒细胞百分比更高(<0.001)。此外,治疗前后 C 反应蛋白水平和中性粒细胞百分比均值差值比较差异均有统计学意义。多变量分析显示,急性期出现冠状动脉病变和诊断时 C 反应蛋白水平>100mg/L 的患者与 KD 中的 IVIG 耐药相关。在 12 个月的随访期间,组 1 的冠状动脉病变发生率明显高于组 2,组间差异具有统计学意义(<0.001)。

结论:急性期出现冠状动脉病变和 IVIG 治疗前 C 反应蛋白水平升高的患者可能对预测 KD 中的 IVIG 耐药有一定价值。基于治疗前冠状动脉病变和 C 反应蛋白水平进行风险评估可能会改善 IVIG 耐药的结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df55/9365590/1aff87f4caf5/IJCLP2022-2726686.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df55/9365590/a85fb8dd852c/IJCLP2022-2726686.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df55/9365590/1aff87f4caf5/IJCLP2022-2726686.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df55/9365590/a85fb8dd852c/IJCLP2022-2726686.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df55/9365590/1aff87f4caf5/IJCLP2022-2726686.002.jpg

相似文献

[1]
Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.

Int J Clin Pract. 2022

[2]
Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.

Clin Rheumatol. 2023-1

[3]
The role of serum lipid in predicting coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease: a cohort study.

J Int Med Res. 2024-5

[4]
Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.

Pediatr Rheumatol Online J. 2017-3-21

[5]
Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.

Eur J Pediatr. 2023-10

[6]
Predictive Value of Serum Lipid for Intravenous Immunoglobulin Resistance and Coronary Artery Lesion in Kawasaki Disease.

J Clin Endocrinol Metab. 2021-9-27

[7]
Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.

Turk J Pediatr. 2019

[8]
Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease.

Ann Med. 2023

[9]
Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?

Pediatr Infect Dis J. 2018-10

[10]
A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?

Cardiovasc Ther. 2021

引用本文的文献

[1]
Immunophenotype of Kawasaki Disease: Insights into Pathogenesis and Treatment Response.

Life (Basel). 2025-6-25

[2]
Assessing the efficacy of infliximab in promoting vascular and mucosal healing in immunoglobulin-resistant kawasaki disease: a meta-analysis.

BMC Pediatr. 2025-2-27

[3]
C-reactive protein to albumin ratio as a prognostic tool for predicting intravenous immunoglobulin resistance in children with kawasaki disease: a systematic review of cohort studies.

Pediatr Rheumatol Online J. 2024-4-12

[4]
Giant Coronary Aneurysms with Multiple Large Resistant Thromboses in an 8-Month-Old Boy with IVIg-Resistant Kawasaki Disease: A Case Report.

J Tehran Heart Cent. 2023-7

[5]
Predictive factors of medium-giant coronary artery aneurysms in Kawasaki disease.

Pediatr Res. 2024-1

[6]
Bibliometric and visual analysis of Kawasaki disease in children from 2012 to 2022.

Front Pediatr. 2023-7-27

本文引用的文献

[1]
A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?

Cardiovasc Ther. 2021

[2]
Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease.

J Immunol Res. 2020

[3]
Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017-2018.

J Pediatr. 2020-10

[4]
A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.

Rheumatol Int. 2019-7-13

[5]
Comprehensive left ventricular myocardial deformation assessment in children with Kawasaki disease.

Congenit Heart Dis. 2019-11

[6]
Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.

Eur J Pediatr. 2018-6-8

[7]
Prediction for Intravenous Immunoglobulin Resistance by Using Weighted Genetic Risk Score Identified From Genome-Wide Association Study in Kawasaki Disease.

Circ Cardiovasc Genet. 2017-10

[8]
The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.

J Microbiol Immunol Infect. 2017-9-6

[9]
Kawasaki disease: Medical therapies.

Congenit Heart Dis. 2017-9

[10]
Evaluation of myocardial deformation in patients with Kawasaki disease using speckle-tracking echocardiography during mid-term follow-up.

Cardiol Young. 2017-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索